Technologies available for licensing, investment, joint ventures and R&D contracts in Ukraine, Azerbaijan, Georgia, Moldova, Uzbekistan

Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks

Google Translate

Patenting Information

Tag Cloud



Free counters!

Home Biotechnologies Monoclonal antibodies for cancer diagnostics

Monoclonal antibodies for cancer diagnostics

Areas of Application

Early diagnostics of cancer and leukemia. Differential diagnostics of tumors. Immune status evaluation. AIDS monitoring. Monitoring the effectiveness of therapy

Specification

The kits of purified monoclonal antibodies that are produced by hybridomas. The hybridomas from collection produce monoclonal antibodies against CD3, CD4, CD7, CD8, CD10, CD13, CD15, CD16, CD20, CD22, CD25, CD27, CD34, CD37, CD38, CD43, CD45, CD45RA, CD48, CD54, CD56, CD66e, CD95, CD150, CD227, CD326, HLA-ABC, HLA-DR, kappa and lambda light Ig chains, pan-cytokeratin, cytokeratin-18, p53, and antigen of proliferating cells IPO-38. This antibody panel was included to the State register of medical equipment and medical devices of Ukraine and was accepted for the application in medical practice (permanent license).

Advantages

National analogues of these monoclonal antibodies do not exist. Specificity and quality of monoclonal antibodies are not inferior to foreign analogues, but have substantially lower price

Stage of Development. Suggestion for Commercialization

IRL8, TRL7.
Monoclonal antibodies manufacture, purification, specificity testing, supply, quality assurance, and personnel training are provided upon request

IPR Protection

IPR1, IPR3

Contacts

Pyatchanina Tatiana V 
Organization: RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine.
+38044-259-01-67
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Add comment


Security code
Refresh

For additional technologies go to: http://www.stcu.int